Background. Usually, immunoglobulin M (IgM) serologic analysis is not sufficiently specific to confirm Zika virus (ZIKV) infection. However, since IgM does not cross the placenta, it may be a good marker of infection in neonates.
Zika virus (ZIKV) was first detected in northern Brazil in March 2015 in the serum of patients with a dengue-like illness. Phylogenetic analysis demonstrated that the Brazilian strain belonged to the Asian lineage and was highly related to a ZIKV isolate from French Polynesia [1] . By the end of year, the virus had spread to 19 of 27 Brazilian states [2] and, by April 2016, to 34 countries and territories in America. An epidemic of microcephaly started in Brazil in October 2015, 6-7 months after health authorities confirmed ZIKV transmission in the country, and the cluster of microcephaly and other neurological disorders was declared a public health emergency of international concern by the World Health Organization on 1 February 2016 [3] .
Based on the growing evidence that ZIKV was the etiological agent of the microcephaly cluster and other manifestations of Zika syndrome [4] [5] [6] [7] [8] [9] [10] , the causal link between ZIKV and microcephaly was finally recognized [11] . The hesitancy to accept causation in the presence of much circumstantial epidemiological evidence was related to the difficulty of laboratory confirmation in affected infants.
Laboratory diagnosis of ZIKV infection is challenging. In an outbreak of ZIKV infection in Yap Island, Micronesia, in 2007, Lanciotti et al [12] analyzed serum samples from ZIKV-infected patients by using serologic assays, such as detection of immunoglobulin M (IgM) antibodies by an IgM-capture enzyme-linked immunosorbent assay (ELISA) and by a plaque reduction neutralization test (PRNT) to diagnose and evaluate the extent of cross-reactivity among flaviviruses. They found marked cross-reactivity with other flaviviruses, mainly in patients in whom ZIKV infection was secondary to infection with another flavivirus; an accurate diagnosis required combining serologic data to ZIKV detection by molecular methods [12] .
The current recommendation for routine diagnosis of ZIKV infection includes detection of the viral nucleic acid by reversetranscription polymerase chain reaction (RT-PCR), detection of ZIKV-specific IgM antibodies by an ELISA, and performance of a PRNT for confirmation of positive results of the ELISA and exclusion of other flaviviruses [13, 14] . The cross-reactivity of flavivirus antibodies is accepted as the main challenge in the interpretation of serologic test results, especially when the PRNT is not available [12] [13] [14] . Laboratory diagnosis is an essential tool for research and for public health prevention measures. Thus, validation of commercial kits and a better understanding of the performance of currently available kits for detection of IgM antibodies is an urgent priority for diagnosing ZIKV infection.
In this study, we compared results of serologic testing (ELISA) for ZIKV IgM, dengue virus (DENV) IgM and immunoglobulin G (IgG), and ZIKV and DENV neutralizing antibodies in serum from 42 mothers and their neonates born with microcephaly. The levels of ZIKV-specific IgM and neutralizing antibodies in the CSF samples of 30 neonates were also assessed.
METHODS

Population, Study Settings, and Ethical Issues
From 21 to 30 October 2015, we collected samples from 42 neonates with microcephaly and from their mothers. Neonates were born between 5 September and 27 October 2015 in hospitals located in the Metropolitan Region of Recife, Pernambuco State, Brazil. These cases constituted the very first cases of microcephaly identified in this outbreak. No control neonates without microcephaly born in this period were included in this study. Microcephaly was defined as a neonatal occipitofrontal circumference of ≥2 SDs below the mean for gestational age and sex [15] .
We conducted this investigation as part of routine epidemiologic and laboratory surveillance, and therefore ethical committee approval was not required. However, we did collect written informed consent from mothers before participation.
Sample Collection and Processing
We collected blood specimens from 42 mothers and neonates and CSF specimens from 30 neonates; specimens were sent to the Department of Virology at Fiocruz Pernambuco, under refrigeration. Blood samples were spun down for 10 minutes at 1500 ×g, and serum was stored at −80°C. CSF samples were frozen at −80°C without processing. We performed molecular diagnostic assays for ZIKV, DENV, and chikungunya virus (CHIKV) in all specimens from neonates. Serologic tests were performed for DENV and ZIKV in all samples.
Molecular Assays
Serum and CSF specimens were tested by RT-PCR or real-time RT-PCR (qRT-PCR) for detection of ZIKV, DENV, and CHIKV. Viral RNA was extracted using the QIAamp Viral RNA Mini Kit (Qiagen, Valencia, CA) according to the manufacturer's instructions. RT-PCR was performed for ZIKV, using previously described methods with minor modifications [16] in which 2-step RT-PCR was used (ie, complementary DNA synthesis followed by PCR) instead of a 1-step protocol. For DENV, a well-established RT-PCR protocol was used [17] ; for CHIKV, qRT-PCR was performed according to method reported by Lanciotti et al [18] .
Serologic Assays
Detection of DENV IgM and IgG Antibodies
Serum samples from mothers and neonates were first tested for DENV IgM and IgG antibodies by use of the following commercial kits: Dengue IgM-capture ELISA and Dengue IgGcapture ELISA (Pan Bio, Inverness, Australia), following the manufacturer's guidelines.
ELISA for Detection of ZIKV and DENV
Serum and CSF were tested by IgM-capture ELISA, using a protocol described elsewhere [12] and reagents provided by the Centers for Disease Control and Prevention (CDC; Fort Collins, CO). Samples were tested in parallel with ZIKV and DENV antigens to investigate cross-reactivity; reagents were previously titered and diluted as appropriate. Briefly, plates were coated with 75 μL of goat anti-human IgM (Kirkegaard and Perry Laboratories, Gaithersburg, Maryland) in carbonate/bicarbonate ( pH 9.6) and incubated overnight at 4°C. After blocking with phosphate-buffered saline (PBS; pH 7.2) and 5% nonfat dry milk/ 0.05% Tween 20 for 30 minutes at room temperature and washing (done after each step), 50 μL of serum samples diluted 1:400 in PBS ( pH 7.2), 0.05% Tween 20, and undiluted CSF, negative ( pooled flavivirus-negative serum) and positive (CDC humanized 6B6C-1 pan-flavivirus) controls were added, and samples were incubated at 37°C for 1 hour. Viral ZIKV antigen (CDC Vero E6-derived, inactivated ZIKV antigen), normal antigen (CDC Vero E6-derived, mock-infected normal antigen), and DENV antigen (a mixture of the 4 DENV serotypes; Evandro Chagas Institute, Brazil) were then added to each sample (50 μL), and samples were incubated overnight at 4°C. For antibody detection, horseradish peroxidase-conjugated monoclonal antibody (6B6C-1; CDC) diluted in blocking buffer was added, and the sample was incubated for 1 hour at 37°C. The substrate TMB was then added. After incubation for 10 minutes at room temperature, the reaction was stopped with 1NH2SO4 solution, and the OD 450 was determined.
Results are presented as ratios, calculated as follows: mean OD of the test sample reacted with the viral antigen (P) divided by the mean OD of the negative control reacted with the viral antigen (N). P/N values of < 2.0 were considered negative; >3.0, positive; and 2.0-3.0, equivocal. If the sample showed some degree of cross-reactivity, it was considered positive for ZIKV IgM only when the ZIKV P/N was at least twice the DENV P/N.
PRNTs
PRNT 50 values, defined as the PRNT end point at which the highest serum dilution inhibited ≥50% of the plaques, were determined following a modified protocol previously described elsewhere [19] . Briefly, tests were carried out on Vero cells seeded at the density of 300 000 cells/mL using 24-well plates. The assay was performed after serum (inactivated for 30 minutes at 56°C) and CSF were serially diluted (dilutions, 1:20 to 1:20 480) and 100 plaque-forming units (PFU) of challenge virus, previously titered, was incubated. Viruses were isolated in Pernambuco State and molecularly characterized as follows: ZIKV, Brazil-PE243/2015; DENV-1, BR-PE/97-42735; DENV-2, BR-PE/95-3808; DENV-3, BR-PE/02-95016; and DENV-4, BR-PE/12-008. ZIKV and DENV serotype-specific antibodies titers were calculated using a 4-parameter nonlinear regression.
Data Preparation and Analysis
The median values were calculated using the Wilcoxon test for pared samples. DENV serotype-specific and ZIKV neutralizing antibody titers (ie, PRNT 50 values) were estimated using a 4-parameter nonlinear regression. Statistical analysis was performed using Graph Pad Prism, version 6.0e.
Primary ZIKV infection was considered present if the subject tested negative for DENV IgG by ELISA and positive for ZIKV IgM by ELISA, with confirmation by a PRNT positive for ZIKV only. Secondary flavivirus/ZIKV infection was confirmed if the neonate tested positive for DENV IgG and ZIKV IgM by ELISA and had positive results of PRNTs for ZIKV and any DENV serotype. In the text, we present results for all 42 mother-neonate pairs in the text, and in the tables we presented findings for the 30 neonates from whom a CSF sample was available.
RESULTS
Mothers were young (age, 15-38 years); 13 (31%) were <20 years old; 21 (50%) were 20-29 years old, and 8 (19%) were 30-38 years old. Twenty-six of 42 mothers (62%) reported rash during pregnancy, with 23 cases in the first trimester and 3 in the second trimester; fever was reported only by 12 of 26 mothers with rash. Thirteen of 42 (31%) denied any symptoms consistent with viral infection during pregnancy. ZIKV, DENV, and CHIKV viral genomes were not detected in serum or CSF samples by RT-PCR and/or qRT-PCR.
None of the 42 mother-neonate paired serum samples had IgM antibodies to DENV. However, 83.3% of mothers and their babies had DENV IgG antibodies in serum. In the remaining 16.7% (7 of 42), DENV IgG was not detected in serum, which was confirmed by PRNT. Thirteen of 42 mothers (31%) had ZIKV IgM antibodies detected in serum; of the remaining mothers, 29 of 42 (69%) were negative. In neonates, 38 of 42 (90.5%) of serum specimens were positive for ZIKV IgM antibodies; the remaining 4 neonates (9.5%) had ZIKV IgMnegative samples. Importantly, ZIKV IgM antibodies were detected in all 30 samples of CSF obtained from neonates with microcephaly.
Results of serologic testing for the subset of 30 mother-neonate pairs in which the neonate had CSF collected are shown in the tables. Tables 1 and 3 present results for the pairs in which ZIKV was a primary flavivirus infection (eg, those without DENV IgG in serum) and Tables 2 and 4 for those in which ZIKV was a secondary infection (for pairs with DENV IgG in serum). Table 1 presents results of DENV IgG, ZIKV IgM, and DENV IgM in 7 mother/neonate pairs without DENV IgG in serum (ie, those with primary ZIKV infection). The IgM antibody response in neonates with primary ZIKV infection was specific for ZIKV in 6 of 7 CSF specimens (85.7%). In one (case 12), ZIKV IgM antibodies cross-reacted with DENV IgM antibodies; case 21 had a monotypic ZIKV IgM response in CSF (P/N value, 15.6), but the test for IgM in serum yielded an equivocal result (P/N value, 2.1; Table 1) . Table 2 shows results of 23 mother-neonate pairs in which ZIKV was a secondary flavivirus infection. Of these, 11 mothers (47.8%) were positive for ZIKV IgM. Among neonates, ZIKV IgM antibodies were detected in all 23 CSF samples and in 21 serum samples (91.3%). A monotypic ZIKV IgM antibody response was present in 18 of 20 CSF specimens from the 20 cases; all demonstrated low levels of cross-reactive IgM, as shown by a dengue P/N value in the equivocal range (2.0-3.0).
The presence of ZIKV IgM in CSF and serum was concordant in 95.6%. Among the 30 CSF specimens tested for ZIKV IgM, 24 yielded monotypic results, and only 6 revealed cross-reactivity with DENV. Figure 1A shows ZIKV IgM results for CSF specimens (median, 14.9 [range, 9.3-16.4]) and sera (median, 8.9 [range, 2.1-20.6]; P = .0003).
A subset of the neonates with suspected ZIKV infection for whom paired serum and CSF specimens had been collected was analyzed using the PRNT to search for specific ZIKV and DENV neutralizing antibodies and to evaluate the extent of cross-reactivity with related flavivirus. Table 3 shows the PRNT 50 values for the 7 primary ZIKV infections. Mother and neonate serum and CSF samples had specific neutralizing antibodies only for ZIKV, confirming the ELISA results for ZIKV IgM presented in Table 1 . PRNT 50 values also showed that the neutralizing antibody response among patients with primary ZIKV infection was highly specific.
All 18 cases of secondary ZIKV infection (mothers and neonates; Table 4 ) had high titers of neutralizing antibodies to ZIKV; the median titer was 2072 (range, 232-12 980) for mothers and 2730 (range, 398-12 980) for neonates (P < .0001); in CSF specimens, the median neutralizing antibody titer was lower than in serum specimens (93 [range, 40-578]; P < .0001; Figure 1B ). The presence of neutralizing antibodies to DENV serotypes in serum specimens from neonates was similar that in serum specimens from mothers. However, in CSF samples, the neutralizing antibodies were exclusively to ZIKV. There was a remarkably good concordance between anti-ZIKV IgM results in CSF and serum specimens from neonates and PRNT results. Eleven mothers had neutralizing antibodies to DENV-3 and DENV-4; 4, to DENV-4; 1, to DENV-3; and 1, to all DENV serotypes. Of 7 mothers with negative results of serologic tests for DENV, 28.6% had ZIKV IgM antibodies in serum; of 23 mothers who tested positive for DENV, 11 (47.8%) had ZIKV IgM antibodies in serum.
DISCUSSION
It is known that IgM antibodies to DENV can be detected at least 90 days after the onset of symptoms [20] , but it is not known how long ZIKV IgM antibodies remain detectable after infection in blood and in cerebrospinal fluid of neonates with microcephaly. Because 23 of 26 mothers who reported rash indicated that the rash was in the first trimester of pregnancy, it is likely that ZIKV infection would have occurred at least 6 months prior birth. Although we cannot be sure of when the infections have occurred, it is possible that ZIKV IgM antibodies can remain for >90 days. Prospective studies are needed to elucidate the duration.
Surprisingly, none of the mothers in this study reported the presence of rash in the third trimester of pregnancy. It is possible that 31% of them experienced asymptomatic ZIKV infection. There is evidence that the virus can persist for long time in the central nervous system (CNS) of fetuses [6] , but we could not detect ZIKV RNA in the neonate CSF samples.
In our study, subjects with specimens that were ZIKV IgM positive and DENV IgM negative by ELISA were initially considered as having presumptive recent ZIKV infection, and ZIKV infection in these individuals was confirmed by PRNT findings. We found that 90.5% and 97% of neonates had ZIKV IgM antibodies in serum and CSF, respectively, indicating that the embryo or the fetal brain was exposed.
In the ZIKV epidemic in Yap State, Micronesia, patient with secondary flavivirus infection had a higher degree of serologic cross-reactivity with other flaviviruses than primary flavivirus/ ZIKV-infected patients [12] . This was much less marked in the neonates in our study; serologic cross-reactivity with DENV was observed in only 5 of 23 secondary infections (21.7%) and only 1 (14.3%) among the 7 primary ZIKV infections. The antibody response to ZIKV was monotypic in 78.3% of the secondary flavivirus/ZIKV infections (18 of 23). The most probable explanations for this finding are that IgM does not cross the placental barrier, at least to a significant degree, and that, since these Abbreviation: PRNT50, PRNT end point at which the highest serum dilution inhibited ≥50% of the plaques.
samples were collected in the perinatal period, these neonates probably have not been directly exposed to other flaviviruses, except for ZIKV, in the uterus. Moreover, detection of IgM in the CSF indicates the presence of antigen-specific B cells in the brain and a high specificity of the IgM-capture ELISA. In contrast, the neonates had maternal IgG and, hence, also anti-DENV IgG; for neonates, the IgG-based diagnostic assay has low specificity. Consistent with findings from the Yap study, our PRNT results have shown higher titers of neutralizing antibody to ZIKV. However, in contrast to the Yap study [12] , in our study, crossreactivity between ZIKV and DENV was not observed, although both viruses are circulating in our region. In Pernambuco State, yellow fever vaccination is not compulsory, and the region is not at risk for sylvatic yellow fever virus. Because none of the mothers were vaccinated against yellow fever virus, this virus was not tested in the PRNT.
Neutralizing antibody responses to DENV were mainly to DENV-3 and DENV-4 (only 1 mother presented antibodies to DENV-1 and DENV-2, and 1 had antibodies to all 4 DENV serotypes). Because the mothers were young, these findings reflect the epidemiology of DENV circulation in Pernambuco State in the last 30 years, with DENV-1 introduced in 1987, DENV-2 in 1994, and DENV-3 in 2002; DENV-3 predominated until DENV-4 introduction, in 2010 [19] [20] [21] [22] [23] .
Our study adds important evidence that supports the etiological relationship between ZIKV infection of the CNS and microcephaly. We found that 97% of the microcephalic infants had ZIKV IgM in the CNS. Since IgM does not normally cross either the placenta or the blood-brain barrier, detection of virus-specific IgM in the CSF is a significant diagnostic finding, indicating that the neonate had a CNS ZIKV infection during pregnancy [23] .
Detection of neutralizing antibodies to ZIKV in the neonates' CSF samples corroborates the ZIKV IgM-positive results and indicates that detection of ZIKV IgM in neonates' blood or CSF is a good diagnostic tool. The relevance of this study is that these were the first cases of microcephaly identified in Recife in September 2015 that sparked the investigation to determine the cause of the outbreak. Although this study lacks samples from control neonates for comparison, our findings provide additional evidence suggesting that the abnormal brain findings are a consequence of congenital ZIKV infection. Moreover, on the basis of these results, we conclude that identification of anti-ZIKV IgM in the neonate serum during the perinatal period is confirmatory of congenital ZIKV infection. Therefore, we recommend that neonates suspected of having congenital ZIKV infection should be tested for anti-ZIKV IgM and that the PRNT could be used to elucidate equivocal cases. 
Notes
